Having trouble accessing articles? Reset your cache.

KRN5500: Additional Phase IIa data

A subset analysis of 17 patients with chemotherapy-induced peripheral neuropathy (CIPN) from a double-blind, dose-escalation, U.S. Phase IIa trial showed

Read the full 205 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE